Last-Resort access to experimental cell therapy for blood cancer patients
NCT ID NCT07346105
First seen Jan 26, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This program gives patients with certain blood cancers access to Orca-T, a cell therapy, only when their prescribed commercial version is out of specification or expired. The goal is to provide treatment when no other option is available, but it is not a cure and requires ongoing monitoring. Participants must have already been prescribed Orca-T and meet safety criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.